Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

By Tran Hai   Zinner Ralph   Blumenschein George   Oh Yun   Papadimitrakopoulou Vassiliki   Kim Edward   Lu Charles   Malik Mubashira   Lum Bert   Herbst Roy  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 499-505

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer

By Argiris Athanassios   Kut Victoria   Luong Lynn   Avram Michael  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 203-212

Springer Publishing Company

Access to resources Recommend Favorite

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer

By Goto Yasushi  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1548-1556

Springer Publishing Company

Access to resources Recommend Favorite

Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer

By Schuette W.  

Clinical Drug Investigation, Vol. 21, Iss. 3, 2001-03 ,pp. : 161-168

Adis International

Access to resources Recommend Favorite

Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination

By Esteban-Gonzalez Emilio   Fernández Yolanda   Villanueva Noemí   Fra Joaquin   Muñiz Isabel   Palacio Isabel   Vieitez Jose   Uña Esther   Mareque Beatriz   Lacave Angel  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 597-601

Springer Publishing Company

Access to resources Recommend Favorite